SGN-516 by SGN Nanopharma for Diabetic Neuropathy: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN-516 overview
SGN-516 is under development for the treatment of diabetic neuropathy. It is administered through topical route. It is being developed based on Micellar Nanoparticle (MNP) platform.
SGN Nanopharma overview
SGN Nanopharma is a clinical-stage nanomedicine company. It combines its proprietary nanotechnologies with structural biology to develop nanotherapeutics. The company focuses on developing novel therapies, reformulating FDA approved, sub-optimal drugs, and active pharmaceutical ingredients (APIs). It utilizes Micellar Nanoparticle (MNP) technology platform which leads to finer particle sizes and stable nanoemulsions. SGN Nanopharma nanotechnology enables reformulation and delivery of poorly-water-soluble compounds such as cannabinoids. The company introduced a MNP-Cyclosporine formulation for dry eye disease in India and operates through its subsidiary in India. It holds rights to two pending patent families with the United States Patent and Trademark Office (USPTO). SGN Nanopharma is headquartered in Tampa, Florida, the US.
For a complete picture of SGN-516’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
